139 related articles for article (PubMed ID: 27731785)
1. [Not Available].
Osthoff M; Bättig V; Khanna N
Ther Umsch; 2016; 73(8):475-481. PubMed ID: 27731785
[No Abstract] [Full Text] [Related]
2. Real-life use of isavuconazole outside the hematological wards.
Scabini S; Lupia T; Angilletta R; De Rosa FG; Corcione S
Eur J Intern Med; 2019 Dec; 70():e10-e12. PubMed ID: 31526649
[No Abstract] [Full Text] [Related]
3. Isavuconazole: is there a need for a new antifungal?
Cornely OA
J Antimicrob Chemother; 2017 Mar; 72(suppl_1):i2-i4. PubMed ID: 28355461
[No Abstract] [Full Text] [Related]
4. Isavuconazonium sulfate approved for invasive fungal infections.
Traynor K
Am J Health Syst Pharm; 2015 Apr; 72(8):592. PubMed ID: 25825173
[No Abstract] [Full Text] [Related]
5. Novel triazole antifungal drugs: focus on isavuconazole, ravuconazole and albaconazole.
Pasqualotto AC; Thiele KO; Goldani LZ
Curr Opin Investig Drugs; 2010 Feb; 11(2):165-74. PubMed ID: 20112166
[TBL] [Abstract][Full Text] [Related]
6. Isavuconazole-induced Acute Liver Failure in a Pediatric Patient With Invasive Aspergillosis.
Brivio E; Verna M; Migliorino GM; Foresti S; Zucchini N; Rovelli A
Pediatr Infect Dis J; 2019 Oct; 38(10):1035-1037. PubMed ID: 31568141
[TBL] [Abstract][Full Text] [Related]
7. Improvement in Exophiala dermatitidis airway persistence and respiratory decline in response to interferon-gamma therapy in a patient with cystic fibrosis.
Eades CP; Armstrong-James DPH; Periselneris J; Jones A; Simmonds N; Kelleher P; Shah A
J Cyst Fibros; 2018 May; 17(3):e32-e34. PubMed ID: 29456196
[No Abstract] [Full Text] [Related]
8. Serial monitoring of isavuconazole blood levels during prolonged antifungal therapy.
Furfaro E; Signori A; Di Grazia C; Dominietto A; Raiola AM; Aquino S; Ghiggi C; Ghiso A; Ungaro R; Angelucci E; Viscoli C; Mikulska M
J Antimicrob Chemother; 2019 Aug; 74(8):2341-2346. PubMed ID: 31119272
[TBL] [Abstract][Full Text] [Related]
9. A phase 2, randomized, double-blind, multicenter trial to evaluate the safety and efficacy of three dosing regimens of isavuconazole compared with fluconazole in patients with uncomplicated esophageal candidiasis.
Viljoen J; Azie N; Schmitt-Hoffmann AH; Ghannoum M
Antimicrob Agents Chemother; 2015 Mar; 59(3):1671-9. PubMed ID: 25561337
[TBL] [Abstract][Full Text] [Related]
10. Treatment outcomes in patients with proven/probable vs possible invasive mould disease in a phase III trial comparing isavuconazole vs voriconazole.
Maertens J; Selleslag D; Heinz WJ; Saulay M; Rahav G; Giladi M; Aoun M; Kovanda L; Kaufhold A; Engelhardt M; Cornely OA; Herbrecht R; Ullmann AJ
Mycoses; 2018 Nov; 61(11):868-876. PubMed ID: 30035825
[TBL] [Abstract][Full Text] [Related]
11. Isavuconazole shortens the QTc interval.
Mellinghoff SC; Bassetti M; Dörfel D; Hagel S; Lehners N; Plis A; Schalk E; Vena A; Cornely OA
Mycoses; 2018 Apr; 61(4):256-260. PubMed ID: 29178247
[TBL] [Abstract][Full Text] [Related]
12. Isavuconazole for treatment of rare invasive fungal diseases.
Cornely OA; Mullane KM; Ostrosky-Zeichner L; Maher RM; Croos-Dabrera R; Lu Q; Lademacher C; Perfect JR; Oren I; Schmitt-Hoffmann AH; Giladi M; Marty FM; Rahav G
Mycoses; 2018 Aug; 61(8):518-533. PubMed ID: 29611246
[TBL] [Abstract][Full Text] [Related]
13. Isavuconazonium sulfate: a new agent for the treatment of invasive aspergillosis and invasive mucormycosis.
Kovanda LL; Maher R; Hope WW
Expert Rev Clin Pharmacol; 2016 Jul; 9(7):887-97. PubMed ID: 27160418
[TBL] [Abstract][Full Text] [Related]
14. Isavuconazole and voriconazole for the treatment of chronic pulmonary aspergillosis: A retrospective comparison of rates of adverse events.
Bongomin F; Maguire N; Moore CB; Felton T; Rautemaa-Richardson R
Mycoses; 2019 Mar; 62(3):217-222. PubMed ID: 30570179
[TBL] [Abstract][Full Text] [Related]
15. Editorial commentary: Antifungal therapeutic drug monitoring progress: getting it right the first time.
Andes D; Lepak A
Clin Infect Dis; 2012 Aug; 55(3):391-3. PubMed ID: 22610924
[No Abstract] [Full Text] [Related]
16. What should be the first-choice strategy to maximize posaconazole exposure in daily clinical practice?
Pea F; Furlanut M; Viale P
Antimicrob Agents Chemother; 2009 Aug; 53(8):3608-9; author reply 609-10. PubMed ID: 19617468
[No Abstract] [Full Text] [Related]
17. Evaluation of the pharmacokinetics and clinical utility of isavuconazole for treatment of invasive fungal infections.
Livermore J; Hope W
Expert Opin Drug Metab Toxicol; 2012 Jun; 8(6):759-65. PubMed ID: 22530880
[TBL] [Abstract][Full Text] [Related]
18. An update on the safety and interactions of antifungal drugs in stem cell transplant recipients.
Girmenia C; Iori AP
Expert Opin Drug Saf; 2017 Mar; 16(3):329-339. PubMed ID: 28004589
[TBL] [Abstract][Full Text] [Related]
19. Hepatic veno-occlusive disease during isavuconazole administration.
Mesini A; Cangemi G; Palmisani E; Dufour C; Castagnola E
J Chemother; 2018 Feb; 30(1):63-64. PubMed ID: 29278102
[No Abstract] [Full Text] [Related]
20. Pharmacokinetics of oral isavuconazole in a patient after Roux-en-Y gastric bypass surgery.
Knoll BM
J Antimicrob Chemother; 2014 Dec; 69(12):3441-3. PubMed ID: 25114167
[No Abstract] [Full Text] [Related]
[Next] [New Search]
